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Abstract
Objective—This study sought to measure residual contraceptive hormone levels in vaginal rings 
as an adherence marker for monitoring product use in clinical trials.
Study design—Residual etonogestrel and ethinyl estradiol levels from used NuvaRings® of 26 
self-reported adherent women enrolled in a clinical trial of vaginal ring acceptability were 
compared to those from 16 women who used NuvaRing® as their contraceptive choice.
Results—Twenty-one (81%) clinical trial rings had contraceptive hormone levels within the 
range of those used as a contraceptive choice. Five returned rings had unused or discordant levels 
of residual contraceptive hormones.
Conclusion—Residual vaginal ring drug levels could help assess adherence in clinical trials.
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1. Introduction
Prevention of HIV sexual transmission through antiretroviral (ARV) drugs as preexposure 
prophylaxis (PrEP) can be highly effective when individuals adhere to prescribed ARV 
regimens [1]. Measuring adherence to PrEP regimens has relied primarily on participant 
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self-report that can be unreliable (e.g., overreporting, recall issues, social desirability) or 
blood ARV concentrations that may not provide accurate measures of cumulative drug 
exposure over extended periods of use [2]. HIV PrEP interventions currently in development 
include multipurpose vaginal rings containing ARVs to prevent sexual transmission of HIV 
in addition to hormonal contraceptives to prevent pregnancy [3]. New analytical approaches 
to assess adherence to multipurpose vaginal rings are needed to better evaluate the safety and 
efficacy of these new intervention strategies [2,4,5]. Residual levels of the ARV dapivirine in 
used vaginal rings have recently been used to inform measures of adherence and efficacy for 
vaginal rings in clinical trials for HIV prevention [5,6]. Our study sought to determine if 
residual synthetic hormone levels in used contraceptive vaginal rings could provide an 
objective measure of vaginal ring use during a clinical trial.
2. Materials and methods
Sixteen NuvaRings® were collected following 21 days of self-reported use from female 
volunteers using NuvaRing® as their method for contraception at the Emory University 
Student Health and Counseling Services in Atlanta, GA. Another 26 NuvaRings® were 
collected from women in Kisumu, Kenya, who self-reported complete adherence to the 
prescribed 21 days of NuvaRing® use during the first month of a clinical trial of 
acceptability, adherence and biologic effects of a contraceptive vaginal ring. NuvaRings® in 
sealed packaging from the manufacturer were considered to be unused rings for comparison. 
We extracted residual etonogestrel and ethinyl estradiol from NuvaRings® using ethyl 
acetate and measured synthetic hormones using high-performance liquid chromatography as 
previously described (Supplementary Methods) [7]. Used and unused rings were extracted 
and measured in parallel to calculate the amount of residual etonogestrel and ethinyl 
estradiol in the used rings as a percentage of that measured in unused rings. We considered 
used rings with residual etonogestrel and ethinyl estradiol levels greater than 95% of those 
measured in unused rings to be indistinguishable from unused rings (Supplementary 
Methods).
3. Results
The 16 vaginal rings from United-States-based female volunteers using NuvaRing® as their 
chosen contraceptive method had relatively narrow ranges of residual etonogestrel (mean 
75% of unused rings; range 70%–79%) and ethinyl estradiol (mean 86% of unused rings, 
range 80%–91%; Fig. 1). Three volunteers reported removing the vaginal ring for less than 1 
day during the prescribed 21 days of use, but the residual synthetic hormone levels in these 
used rings were indistinguishable from the other 13 rings from this group (Fig. 1). Based on 
the values from these 16 vaginal rings, we established adherent NuvaRing® use ranges 
(mean ± 2 standard deviations) for residual etonogestrel (69%–81%) and ethinyl estradiol 
(79%–93%) to evaluate vaginal rings collected during the Kenya clinical trial of NuvaRing®.
Twenty-one (81%) of 26 vaginal rings from Kenyan participants had both residual 
etonogestrel and ethinyl estradiol values within the adherent ranges derived from current 
users in the United States (Fig. 1, Table 1). Three (12%) vaginal rings had residual 
etonogestrel and ethinyl estradiol levels indistinguishable from those in unused NuvaRings® 
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(Fig. 1, Table 1). Discordant results between residual etonogestrel and ethinyl estradiol 
levels were obtained for one vaginal ring (Table 1). One vaginal ring contained residual 
ethinyl estradiol consistent with adherent use but residual etonogestrel (88%) greater than 
levels consistent with adherent use yet less than levels in unused rings (Table 1). To see if 
unused or discordant contraceptive hormone results may have been influenced by 
intravaginal factors, we compared the distribution of diagnosed bacterial vaginosis (BV) 
among the adherent and discordant groupings. BV diagnosis was not available from current 
users in the United States but was diagnosed in eight Kenyan participants based on Nugent 
score: five with adherent contraceptive hormone levels, two with levels indistinguishable 
from unused NuvaRings® and one with discordant levels (Fig. 1).
4. Discussion
Analytical measures of product adherence such as hormone concentrations in blood are 
invasive, costly and unable to indicate cumulative product use. As safety and efficacy 
evaluations of multipurpose vaginal rings begin, new analytical approaches for assessing 
adherence to these interventions are needed to accurately measure cumulative usage over 
extended periods of prescribed use. In this study, we measured residual contraceptive 
hormones to provide an analytical measure of vaginal ring adherence during a clinical trial 
among a population of women for whom contraceptive vaginal rings are not currently 
available. Many returned NuvaRings® (81%) from Kenyan clinical trial participants 
contained residual contraceptive hormone levels consistent with adherent use as determined 
by current NuvaRing® users, suggesting that residual compounds can provide a measure of 
vaginal ring adherence. Measuring two contraceptive hormones produced concordant results 
in 92% of returned vaginal rings, increasing confidence in our assessment of adherence for 
these vaginal rings. It is not known if discordant residual levels in vaginal rings resulted 
from unreported vaginal ring manipulations such as usage patterns, from storage conditions 
or from intravaginal factors affecting atypical contraceptive hormone release. It is unclear 
how best to interpret the result of 81%–95% residual etonogestrel as it may be an indication 
of partial use or biological factors affecting contraceptive hormone release. While 
contraceptive vaginal rings are not currently licensed for use in Kenya, our results suggest 
that Kenyan women seeking contraception are likely to use vaginal rings as prescribed for at 
least 1 month; however, previous studies suggest that adherence to vaginal rings can decline 
over time [8,9]. Longitudinal analysis of used vaginal rings from clinical trial participants 
will provide better insight into long-term acceptability among women not accustomed to 
using vaginal rings.
Evaluation of vaginal ring use among clinical trial participants in this study is limited by 
reliance on self-reported use by current NuvaRing® users in the United States for 
establishing residual contraceptive hormone adherence ranges. Careful selection of 
appropriate population-based controls is essential to accurately define vaginal ring 
adherence in clinical studies. Additionally, variability among biological factors such as 
vaginal pH, mucus, microflora or STIs may influence release rates of compounds from 
vaginal rings, and the prevalence of these factors can differ between populations [10]. Our 
preliminary evaluation of BV distribution with vaginal ring residual outcomes did not reveal 
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an observable effect of BV on contraceptive hormone release that may affect adherence 
measures, but should be done with a larger sample size.
Multipurpose vaginal rings and new contraceptive vaginal rings in development are building 
upon existing technology used in NuvaRing® to improve and control compound release [3]. 
While the methodology may need to be amended to fit each new product, the testing 
approach presented here provides a basis for applying new analytical measures of vaginal 
ring adherence applicable to multipurpose vaginal rings and new contraceptive vaginal rings. 
Studies that merge analytical outcomes such as residual contraceptive hormone levels with 
behavioral measures will provide a more accurate assessment of vaginal ring safety and 
efficacy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Residual etonogestrel and ethinyl estradiol measured in NuvaRings® collected from current 
users and clinical trial participants following 1 month of self-reported use. Residual 
etonogestrel and ethinyl estradiol were calculated as a percentage of those measured in 
unused NuvaRings®. Blue circles and green circles indicate current NuvaRing® users and 
Kenyan clinical trial participants, respectively. Unfilled circles (n=3) indicate current users 
who reported removal of NuvaRing® during prescribed use. Red circles (n=8) indicate 
clinical trial participants diagnosed with BV.
Haaland et al. Page 6

























Haaland et al. Page 7
Table 1
Comparison of residual etonogestrel and ethinyl estradiol measured in NuvaRings collected from clinical trial 
participants (2014–2015)






Residual etonogestrel <81% (+), >96% (−) and between 81% and 96% (+/−).
b
Residual ethinyl estradiol <93% (+) and >95% (−).
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